Abstract: We analyzed the earnings revisions of HSI component stocks for May 2026, estimating the index's 2026E EPS at HK$2,199 as of end-May, up 0.12% month-on-month from HK$2,196 in April. The HSI index fell 1.7% over the month, from 25,777 to 25,328, with 47 stocks seeing upward EPS revisions versus 28 downward. The top positive contributors to index EPS were CCB (+HK$2.99), ICBC (+HK$2.60), and HSBC (+HK$1.95), while the largest detractors were MEITUAN (-HK$4.32), XIAOMI (-HK$3.27), and Kuaishou (-HK$1.96). At the stock level, the sharpest EPS upgrades were MEITUAN (+314%) and Orient Overseas (+16.6%), while the deepest cuts were LI AUTO (-27.5%), BYD Electronic (-22.1%), and Kuaishou (-8.3%). On revenues, Innovent Biologics led upgrades (+5.97%) while CK Infrastructure saw the steepest decline (-9.02%).
ICBC, LAOPU GOLD, INNOVENT BIOLOGICS, MEITUAN, SINO BIOPHARMACEUTICAL, BYD Electronic
A monthly review of consensus earnings revisions for HSI constituents. Each issue estimates how the index's forward EPS changed over the month, and tabulates the stocks with the largest impact on index EPS alongside their EPS and revenue revisions. All issues of Index Earnings Revision Monthly →
Interested in the full report? Get in touch with our team.